沈雳,王齐兵,吴轶喆,谢建,张峰,葛雷,葛均波

• 1:复旦大学附属中山医院上海市心血管病研究所
• 2:上海微特生物技术有限公司

摘要(Abstract)：

目的评价新型全降解聚乳酸西罗莫司洗脱支架(XinsorbTM)在小型猪冠状动脉抑制新生内膜增殖的有效性和安全性。方法裸金属支架(Bare metal stent,BMS)16枚和Xinsorb支架16枚分别随机置入16头小型猪的前降支(16枚)和右冠状动脉(16枚)。置入30d和90d,复查冠状动脉造影后处死部分动物取出支架段血管,将支架分成等长的两部分,一半用树脂包埋后制作硬组织切片,苏木素和伊红染色(haematoxylin and eosin,HE)分析组织形态,评价新生内膜增殖及管腔狭窄率;另一半用戊二醛固定后用扫描电镜观察支架段血管内皮化情况。结果 Xinsorb支架置入后未出现支架内血栓,并有效防止血管弹性回缩造成的血管狭窄。病理分析提示:置入30d,Xinsorb支架比BMS能显著减少新生内膜面积(0.9±0.2)mm2比(2.2±0.2)mm2(P<0.05)和管腔狭窄面积(19.3±3.4)%比(38.2±5.3)%(P<0.05),置入30d时BMS内皮化完全,但Xinsorb支架表面有部分未完全内皮化,Xinsorb支架内皮化完全所需的时间在30～90d。结论 Xinsorb支架在置入小型猪冠状动脉90d内,可以有效地支撑血管壁防止弹性回缩并抑制新生内膜增殖,在置入早期轻度延迟内皮的修复。

关键词(KeyWords)： 药物洗脱支架;冠状动脉再狭窄;内皮,血管;西罗莫司

Abstract:

Keywords:

基金项目(Foundation): 国家重点基础研究发展计划(2011CB503905);; 上海市科学技术委员会资助(11441900300);; 上海市青年科技启明星(跟踪)计划(11QH1400500)

作者(Author): 沈雳,王齐兵,吴轶喆,谢建,张峰,葛雷,葛均波

参考文献(References)：

• [1]Sousa JE,Costa MA,Sousa AGMR.Two-year angiographic and intravascular ultrasound follow-up after implantation of sirolimus-eluting stents in human coronary arteries.Circulation,2003,107:381-383.
• [2]Stone GW,Ellis SG,Cox DA.A polymer-based,paclitaxel-eluting stent inpatients with coronary arteries diseases.New Eng J Med,2004,350:221-231.
• [3]Joner M,Finn AV,Farb A,et al.Pathology of drug-eluting stents in humans:delayed healing and late thrombotic risk.J Am Coll Cardiol,2006,48:193-202.
• [4]Luscher TF,Steffel J,Eberli FR,et al.Drug-eluting stent and coronary thrombosis:biologicalmechanisms and clinical implications.Circulation,2007,115:1051-1058.
• [5]Kotani J,Awata M,Nanto S,et al.Incomplete neointimal coverage of sirolimus-eluting stents:angioscopic findings.J Am Coll Cardiol,2006,47:2108-2111.
• [6]Wilson GJ,Nakazawa G,Schwartz RS,et al.Comparison of inflammatory response after implantation of sirolimus-and paclitaxel-eluting stents in porcine coronary arteries.Circulation,2009,120:141-149.
• [7]Kimura T,Yokoi H,Nakagawa Y,et al.Three-year follow-up after implantation of metallic coronary artery stents.N Engl J Med,1996,334:561-566.
• [8]Ge J,Qian J,Wang X,et al.Effectiveness and Safety of the Sirolimus-Eluting Stents Coated With Bioabsorbable Polymer Coating in Human Coronary Arteries.Catheter Cardiovasc Interv,2007,69:198-202.
• [9]Windecker S,Serruys PW,Wandel S,et al.Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation(LEADERS):a randomised non-inferiority trial.Lancet,2008,372:1163-1173.
• [10]Serruys PW,Kutryk KJ,Ong AT.Coronary-artery stents.N Engl J Med,2006,354:483-495.
• [11]Wykrzykowska JJ,Onuma Y,Serruys PW.Vascular restoration therapy:the fourth revoluation in interventional cardiology and the ultimate"Rosy"prophecy.Eurointervention,2009,5suppl:F7-F8.
• [12]Onuma Y,Serruys PW,Ormiston JA,et al.Three-year results of clinical follow-up after a bioresorbable everolimus-eluting scaffold in patients with de novo coronary artery disease:the ABSORB trial.EuroIntervention,2010,6:447-453.
• [13]Lincoff AM,Furst JG,Ellis SG,et al.Sustained local delivery of dexamethasone by a novel intravascular eluting s ten t to prevent restenosis in the porcine coronary injury model.J Am Coll Cardiol,1997,29:808-816.
• [14]Virmani R,Guaglium IG,Farb A,et al.Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus eluting stent:Should we be cautious?Circulation,2004,109:701-705.